Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.50), $0.05 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $59.6 million versus the consensus estimate of $59.46 million.

“Our team successfully executed on all three of our strategic pillars in 2018. We grew NUPLAZID in Parkinson’s disease psychosis, leveraged pimavanserin in additional large market CNS indications with positive data from our Phase 2 CLARITY study in adjunctive treatment of major depressive disorder, and expanded our CNS pipeline with the acquisition of the North American rights for trofinetide,” said Steve Davis, ACADIA’s Chief Executive Officer. “2019 will be a pivotal year for ACADIA. We are on track to announce top-line data from our Phase 3 pimavanserin study in adjunctive treatment of schizophrenia mid-year. In addition, we expect to realize strong NUPLAZID revenue and volume growth, while advancing our late-stage pipeline.”

GUIDANCE:

Acadia Pharma sees FY2019 revenue of $275-300 million, versus the consensus of $297.15 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.